10-Q quarterly report · filed Nov 16, 2026

Lexeo Therapeutics, Inc. (LXEO) Q3 2026 10-Q Quarterly Report

Short answer

Lexeo Therapeutics, Inc. (LXEO) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$38M
−88.8% YoY · −48.1% QoQ
EPS (diluted)
−$0.44
−131.6% YoY · −46.7% QoQ

Source: XBRL data from the Lexeo Therapeutics, Inc. (LXEO) Q3 2026 10-Q on SEC EDGAR. USD.

Lexeo Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales generated
  • Net loss $38.3M vs $20.3M YoY, operating loss $40.4M vs $21.6M
  • LX2006 R&D $12.7M vs $5.1M, best-performing program by quarterly spending
  • Cash, equivalents and Treasury investments $219.1M vs $246.6M at year-end; operating cash outflow $67.3M
  • Management expects funding into 2028, with continued losses and significantly higher development expenses ahead

Risk Factors

  • Newly added regulatory risk: 2026 legislation codified orphan exclusivity by approved indication and extended pediatric priority vouchers only through September 30, 2029
  • Most materially updated FDA risk: agency reorganization, potential shutdowns, layoffs, and resource constraints could delay reviews, approvals, and inspections
  • Clinical safety risk: LX2006 preclinical studies observed four hepatocellular carcinomas in wild-type mice 10 months after treatment
  • Competitive risk: LX2006 faces Solid Biosciences, Voyager-Neurocrine, Larimar, Design Therapeutics, and PTC Therapeutics programs
  • Liquidity risk: $219.1 million in cash, cash equivalents, and U.S. Treasury investments expected to fund operations into 2028

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Lexeo Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.